DEA Telehealth Flexibility Expiration 2026

Editorial review

Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.

What's Happening With DEA Telehealth Flexibility in 2026

A federal rule that determines whether online ketamine clinics can prescribe without requiring an in-person exam has been extended by the Drug Enforcement Administration (DEA) three separate times since 2023, most recently through December 31, 2025, according to DEA's own rulemaking record. Whether that flexibility continues, changes, or lapses in 2026 directly affects anyone using a telehealth ketamine provider, because it decides whether a video visit alone is enough to get an at-home ketamine prescription or whether an in-person medical evaluation becomes required again.

Ketamine is classified as a Schedule III controlled substance under the federal Controlled Substances Act, the same category as anabolic steroids and some prescription stimulant combinations. That classification is why ketamine telehealth prescribing is governed by DEA telemedicine rules rather than ordinary state telehealth law alone.

Quick Answer

DEA's telemedicine flexibility lets prescribers issue Schedule II through V controlled substance prescriptions, including ketamine, after a telehealth visit alone, without a prior in-person exam. DEA and the Department of Health and Human Services (HHS) extended this flexibility three times since the COVID-19 public health emergency ended in May 2023, with the last confirmed extension running through December 31, 2025. Because DEA has repeatedly issued extensions close to each deadline, confirm the current status directly with DEA's Diversion Control Division and with your provider before assuming your prescribing pathway won't change in 2026.

Why This Rule Exists: The Ryan Haight Act

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires a practitioner to complete at least one in-person medical evaluation before prescribing a controlled substance, with narrow exceptions. During the COVID-19 public health emergency, DEA and the Substance Abuse and Mental Health Services Administration (SAMHSA) used emergency authority to waive that in-person requirement, which is what let telehealth ketamine companies build a model around a video intake and remote screening rather than an office visit.

When the public health emergency ended on May 11, 2023, DEA did not let the flexibility disappear immediately. It issued a temporary rule extending full telemedicine prescribing through November 11, 2023, then a second extension through December 31, 2024, then a third extension through December 31, 2025, citing concern about disrupting care for patients already being treated through telehealth.

Compare your options

Move from the guide into a side-by-side comparison when you are ready to evaluate tradeoffs.

Compare options

This Deadline Has Moved Before

DEA extended its controlled substance telemedicine flexibility three times between 2023 and 2025, each time announcing the extension close to the prior expiration date. That pattern means the rule governing ketamine telehealth in 2026 could change with limited notice. Check the DEA Diversion Control Division's telemedicine page directly, and ask your provider in writing how they plan to stay compliant, rather than relying on secondhand summaries, including this one, for the current deadline.

If the Flexibility Lapses: What Changes for Ketamine Patients

If DEA lets the flexibility expire without a permanent replacement, the Ryan Haight Act's default rule returns: prescribers would generally need to complete at least one in-person medical evaluation before prescribing ketamine, unless a narrower exception applies, such as a prescriber-patient relationship formed under a qualifying telemedicine encounter before the flexibility ended, subject to time limits DEA and HHS have specified in past rulemakings.

DEA has also proposed a permanent "special registration" pathway that would let qualifying telemedicine platforms keep prescribing controlled substances without an in-person exam under added safeguards, such as checking a state prescription drug monitoring program (PDMP) before each prescription. As of this writing, DEA has not finalized that special registration framework, so it is not yet a guaranteed fallback if the temporary flexibility lapses.

Separately, state law can add its own requirements regardless of what DEA decides. Some states already require an in-person visit, a specific patient relationship, or added documentation for controlled substance telehealth prescribing. Review the state-by-state telehealth regulations and the telehealth law changes that took effect in your state before assuming federal flexibility is the only rule that applies to you.

What to Do as a Ketamine Telehealth Patient in 2026

Ask your provider directly how they plan to handle a possible change to the in-person exam requirement, and get the answer in writing rather than relying on marketing copy. A legitimate provider should be able to explain, in plain terms, whether your prescription depends on the current DEA flexibility and what your options are if it changes.

Before you commit to a new provider, or renew with your current one, confirm the prescriber's license and DEA registration are active in your state using a resource like how to verify a ketamine doctor's license before booking. Providers who are vague about their DEA registration status, or who dismiss questions about the telemedicine rule, are worth weighing alongside other online ketamine clinic red flags.

Questions to Ask Before You Rely on Telehealth-Only Ketamine Access

Ask whether your prescription currently relies on the DEA's telemedicine flexibility for controlled substances

Ask what the provider's plan is if that flexibility changes or lapses in 2026

Confirm the prescriber holds an active medical license and DEA registration in your state

Check whether your state has its own in-person or telehealth requirements beyond the federal rule

Get the provider's compliance answer in writing, not just verbal reassurance

Key Takeaway

DEA's telemedicine flexibility affects whether you need an in-person exam to get a ketamine prescription, but it does not replace ongoing safety monitoring. Follow your provider's ketamine telehealth follow up care schedule and use an at home ketamine safety checklist regardless of which prescribing pathway applies to you.

Compare How Providers Handle Compliance

See how vetted telehealth ketamine providers structure screening, prescribing, and follow-up, so you can judge which one fits your situation.

Compare providers

Frequently Asked Questions

Yes. Ketamine is classified as a Schedule III controlled substance under the federal Controlled Substances Act, which is why its telehealth prescribing is governed by DEA telemedicine rules rather than general telehealth law alone.

It depends on whether DEA's telemedicine flexibility remains in effect and on your state's own requirements. Ask your provider directly which pathway they are using and check DEA's telemedicine page for the current federal status before assuming either answer.

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 is the federal law that generally requires a practitioner to conduct at least one in-person medical evaluation before prescribing a controlled substance, subject to specific exceptions that DEA has temporarily expanded since 2023.

Past DEA extensions have included transition provisions for patients with an existing prescriber relationship formed under the flexibility, giving them additional time before an in-person exam would be required. Ask your specific provider how they would apply any such transition period to your care.